
SynBioBeta Speaker
Daniel Georgiev
Sampling Human
CEO & Co-founder
Daniel Georgiev is the founder of Sampling Human, building AI-native, single-cell omics systems that turn complex human biology into scalable, actionable data for the next generation of precision medicine.
Sessions Featuring
Daniel
This Year
•
-
AIxBIO
The Data Reality Check: Human-First Biology for AI Models
Why do so many in silico models fail when moved to the lab or clinic? Too often, they’re trained on incomplete, non-human, or non-representative datasets. This session tackles the “data gap” head-on: from interoperability bottlenecks and the black box problem to the limits of current virtual cell simulations (~50 million perturbations vs. the billions biology demands). Panelists will explore how to create “human-first” datasets that reflect real biology, unlock mechanistic interoperability, and close the discovery–development divide. The goal: build AI tools that can directly identify viable drug candidates instead of stalling in silico.
Featuring

Andrei Georgescu
Vivodyne
CEO

Johnny Yu
Tahoe Therapeutics
CSO & Co-founder

Avantika Lal
Genentech
Principal ML Scientist II
Building DNA foundation models that design regulatory sequences.

Daniel Georgiev
Sampling Human
CEO & Co-founder

Krish Ramadurai
AIX Ventures
Partner
TechBio investor backing AI-designed drugs and breakthroughs.
•
-
AIxBIO
The Data Reality Check: Human-First Biology for AI Models
Why do so many in silico models fail when moved to the lab or clinic? Too often, they’re trained on incomplete, non-human, or non-representative datasets. This session tackles the “data gap” head-on: from interoperability bottlenecks and the black box problem to the limits of current virtual cell simulations (~50 million perturbations vs. the billions biology demands). Panelists will explore how to create “human-first” datasets that reflect real biology, unlock mechanistic interoperability, and close the discovery–development divide. The goal: build AI tools that can directly identify viable drug candidates instead of stalling in silico.
Featuring

Andrei Georgescu
Vivodyne
CEO

Johnny Yu
Tahoe Therapeutics
CSO & Co-founder

Avantika Lal
Genentech
Principal ML Scientist II
Building DNA foundation models that design regulatory sequences.

Daniel Georgiev
Sampling Human
CEO & Co-founder

Krish Ramadurai
AIX Ventures
Partner
TechBio investor backing AI-designed drugs and breakthroughs.
Session lineup still growing
Featuring
Speaker Coming Soon
•
-
Human Health
From Cells to Patients: Solving the Scale Mismatch in Virtual Biology
Drug discovery often measures biology at the cell level while interventions work at the tissue, organ, or whole-patient scale. This mismatch can make accurate cell-level predictions irrelevant in the clinic. This session dives into strategies to bridge that gap: multiscale modeling that nests single-cell dynamics within organ-level simulations, spatial transcriptomics that preserve context, and surrogate models that translate cell-level outputs into clinical biomarkers. Speakers will ask: how do we ensure virtual biology reflects not just what cells do in isolation, but how biology behaves in the real complexity of patients?
Featuring
Speaker Coming Soon





































